Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials / Schuetz, P.; Bolliger, R.; Merker, M.; Christ-Crain, M.; Stolz, D.; Tamm, M.; Luyt, C. E.; Wolff, M.; Schroeder, S.; Nobre, V.; Reinhart, K.; Branche, A.; Damas, P.; Nijsten, M.; Deliberato, R. O.; Verduri, A.; Beghe', B.; Cao, B.; Shehabi, Y.; Jensen, J. -U. S.; Beishuizen, A.; de Jong, E.; Briel, M.; Welte, T.; Mueller, B.. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 16:7(2018), pp. 555-564. [10.1080/14787210.2018.1496331]

Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials

Verduri A.;Beghe' B.;
2018

Abstract

Introduction: Although evidence indicates that use of procalcitonin to guide antibiotic decisions for the treatment of acute respiratory infections (ARI) decreases antibiotic consumption and improves clinical outcomes, algorithms used within studies had differences in PCT cut-off points and frequency of testing. We therefore analyzed studies evaluating procalcitonin-guided antibiotic therapy and propose consensus algorithms for different respiratory infection types. Areas covered: We systematically searched randomized-controlled trials (search strategy updated on February 2018) on procalcitonin-guided antibiotic therapy of ARI in adults using a pre-specified Cochrane protocol and analyzed algorithms from 32 trials that included 10,285 patients treated in primary care settings, emergency departments (ED), and intensive care units (ICU). We derived consensus algorithms for use of procalcitonin by the type of ARI including community-acquired pneumonia, bronchitis, chronic obstructive pulmonary disease or asthma exacerbation, sepsis, and post-operative sepsis due to respiratory infection. Consensus algorithm recommendations differ with regard to timing of treatment (i.e. timing of initiation in low-risk patients or discontinuation in high-risk patients) and procalcitonin cut-off points for the recommendation/strong recommendation to discontinue antibiotics (≤ 0.25/≤ 0.1 µg/L in ED and inpatients, ≤ 0.5/≤ 0.25 µg/L in ICU patients, and reduction by ≥ 80% from peak levels in sepsis patients). Expert commentary: Our proposed algorithms may facilitate safe and efficient implementation of procalcitonin-guided antibiotic protocols in diverse healthcare settings. Still, the decision about initiation and cessation of antibiotic treatment remains a clinical decision based on the patient assessment and the severity of illness and use of procalcitonin should not delay empirical treatment in high risk situations.
2018
16
7
555
564
Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials / Schuetz, P.; Bolliger, R.; Merker, M.; Christ-Crain, M.; Stolz, D.; Tamm, M.; Luyt, C. E.; Wolff, M.; Schroeder, S.; Nobre, V.; Reinhart, K.; Branche, A.; Damas, P.; Nijsten, M.; Deliberato, R. O.; Verduri, A.; Beghe', B.; Cao, B.; Shehabi, Y.; Jensen, J. -U. S.; Beishuizen, A.; de Jong, E.; Briel, M.; Welte, T.; Mueller, B.. - In: EXPERT REVIEW OF ANTI-INFECTIVE THERAPY. - ISSN 1478-7210. - 16:7(2018), pp. 555-564. [10.1080/14787210.2018.1496331]
Schuetz, P.; Bolliger, R.; Merker, M.; Christ-Crain, M.; Stolz, D.; Tamm, M.; Luyt, C. E.; Wolff, M.; Schroeder, S.; Nobre, V.; Reinhart, K.; Branche, A.; Damas, P.; Nijsten, M.; Deliberato, R. O.; Verduri, A.; Beghe', B.; Cao, B.; Shehabi, Y.; Jensen, J. -U. S.; Beishuizen, A.; de Jong, E.; Briel, M.; Welte, T.; Mueller, B.
File in questo prodotto:
File Dimensione Formato  
schuetz2018.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1.08 MB
Formato Adobe PDF
1.08 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
POST PRINT_Procalcitonin-guided antibiotic therapy algorithms.pdf

Open access

Tipologia: Versione dell'autore revisionata e accettata per la pubblicazione
Dimensione 924.82 kB
Formato Adobe PDF
924.82 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1221253
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 47
  • ???jsp.display-item.citation.isi??? 37
social impact